About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit http://www.diagenic.com
DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services.
DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision's service portfolio can be found on http://www.dnavision.com
Corporate Inquiries: Erik Christensen, Managing Director DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway, Tel +47-95939918, Email: firstname.lastname@example.org; Media Inquiries: For DNAVision: Michael Herman, DNAVision, Tel +32-71378527, Email email@example.com
|SOURCE DiaGenic ASA|
Copyright©2008 PR Newswire.
All rights reserved